• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: ECTRIMS 2025

Ocrelizumab use throughout the MS clinical course: highlights from ECTRIMS 2025

October 15, 2025  

Early use and long-term safety of ofatumumab: highlights from ECTRIMS 2025

October 7, 2025  

ECTRIMS 2025 HIGHLIGHTS – SATURDAY, SEPTEMBER 27, 2025

September 27, 2025  

ECTRIMS 2025 HIGHLIGHTS – FRIDAY, SEPTEMBER 26, 2025

September 26, 2025  

ECTRIMS 2025 slide resource

September 25, 2025  

ECTRIMS 2025 HIGHLIGHTS – THURSDAY, SEPTEMBER 25, 2025

September 25, 2025  

ECTRIMS 2025 survey

September 4, 2025  

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Management of refractory epilepsy: highlights from ILAE 2025 posted on October 29, 2025
  • Revised recommendations on the differential diagnosis of MS posted on July 25, 2023
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions